Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
AbbVie (NYSE: ABBV) will present 30 abstracts at the 2022 American Academy of Neurology Annual Meeting, showcasing its leadership in neuroscience. Key highlights include ongoing research on migraine treatments, particularly the newest migraine medicine, atogepant (QULIPTA™), and advancements in therapies for advanced Parkinson's disease. Notable studies will also focus on spasticity and cervical dystonia with data on onabotulinumtoxinA (BOTOX®). The meeting will take place in Seattle from April 2-7, 2022, with virtual presentations from April 24-26.
AbbVie and Allergan Aesthetics will present 12 abstracts and two late-breaking presentations at the 2022 AAD Annual Meeting, showcasing their commitment to dermatologic research. Key highlights include new findings on RINVOQ® and SKYRIZI® in treating atopic dermatitis and psoriasis. Notably, a post-hoc analysis indicates RINVOQ's superior efficacy compared to DUPIXENT® in moderate to severe atopic dermatitis. Allergan will introduce a novel hydrating serum and present data on HA injectable gel for jawline definition. These presentations emphasize the companies' dedication to enhancing patient care in dermatology.
AbbVie announced that the FDA approved RINVOQ (upadacitinib) for treating adults with moderately to severely active ulcerative colitis (UC) who have not adequately responded to TNF blockers. This indicates AbbVie's expansion into gastroenterology with RINVOQ now approved for four indications. In clinical trials, RINVOQ showed higher rates of clinical remission and response, achieving significant outcomes at weeks 8 and 52 compared to placebo. The treatment may cause serious side effects, including infections and cardiovascular risks, warranting careful patient monitoring.
AbbVie announced that LASTACAFT (alcaftadine ophthalmic solution 0.25%) is now available over-the-counter, previously requiring a prescription. This antihistamine eye drop provides relief from itchy allergy eyes caused by seasonal and year-round allergens, working within three minutes and lasting for 16 hours. With an estimated 40% of Americans affected by ocular allergies, this move expands AbbVie's retail eye drop portfolio, alongside the REFRESH product line. LASTACAFT is available in a 5 mL bottle with a 60-day supply or a twin pack for 120 days, enhancing accessibility for allergy sufferers.
AbbVie and Scripps Research have announced a global collaboration to develop new antiviral treatments for COVID-19, aimed at addressing the evolving needs due to new virus variants. The partnership leverages Scripps' expertise and resources, with initial funding support from the Bill & Melinda Gates Foundation. This initiative represents AbbVie's commitment to enhancing access to innovative oral antiviral treatments. The collaboration's success hinges on regulatory approvals and customary closing conditions.
AbbVie and Gedeon Richter have announced a new collaboration to develop novel dopamine receptor modulators targeting neuropsychiatric diseases. This partnership, extending their 15-year relationship, involves shared R&D financing and includes preclinical efforts for new chemical entities. AbbVie will maintain global commercialization rights, with Richter receiving an upfront payment and potential milestone payments. The deal is expected to close in Q2 2022, pending regulatory approvals. This collaboration aims to enhance treatment options for patients with complex neuropsychiatric conditions.
AbbVie announced that the Phase 3 PROGRESS trial for atogepant (QULIPTA™) met its primary endpoint, showing significant reductions in mean monthly migraine days in adults compared to placebo. Patients receiving 60 mg once daily or 30 mg twice daily reported decreases of 6.88 and 7.46 days, respectively. The trial included 778 patients and demonstrated significant improvements across all secondary endpoints. AbbVie plans to submit a supplemental New Drug Application to expand atogepant's use for chronic migraine prevention in the U.S. Safety profiles were consistent with prior studies, with the most common side effects being constipation and nausea.
AbbVie has successfully resolved all patent litigation in the U.S. regarding its HUMIRA (adalimumab) product with Alvotech. Starting July 1, 2023, AbbVie will grant Alvotech a non-exclusive license for HUMIRA-related patents, with Alvotech agreeing to pay royalties. No payments will be made from AbbVie to Alvotech, and the litigation has been dismissed, affirming the validity of AbbVie's patents. This resolution marks a significant milestone in AbbVie's litigation strategy concerning HUMIRA.
Genmab A/S (NASDAQ: GMAB) announced that the FDA has granted orphan-drug designation to epcoritamab (DuoBody®-CD3xCD20) for treating follicular lymphoma (FL). This designation aids the development of treatments for rare diseases affecting fewer than 200,000 people annually. FL is the second most common form of non-Hodgkin’s lymphoma, impacting approximately 2.7 per 100,000 people in the U.S. Epcoritamab is currently in multiple clinical trials, providing hope for patients who are refractory to conventional therapies.
AbbVie (NYSE: ABBV) will participate in the Cowen 42nd Annual Health Care Conference on March 8, 2021, presenting virtually at 11:50 a.m. Central Time. Key executives include Robert A. Michael, Michael E. Severino, M.D., and Jeffrey R. Stewart. A live audio webcast will be available on AbbVie's Investor Relations website, with an archived edition accessible later that day. AbbVie focuses on innovative medicines across various therapeutic areas, including immunology, oncology, and neuroscience, aimed at addressing serious health challenges.